Early experiences with azathioprine in ulcerative colitis; a note of caution.
Early experiences with azathioprine in ulcerative colitis; a note of caution.
复制标题
硫唑嘌呤治疗溃疡性结肠炎的早期经验；
DOI：
10.1001/jama.1966.03100060100027
复制
发表时间：
1966
期刊：
影响因子：
--
通讯作者：
J. Kirsner
中科院分区：
文献类型：
--
作者：
G. E. Bowen;G. V. Irons;J. Rhodes;J. Kirsner
几项信息丰富的研究已经描述了免疫抑制剂在发病机制中归类为自身免疫性疾病中的使用。Dameshek和Schwartz 1，2已经表明，某些抗代谢物能够产生药物诱导的免疫耐受性，理论上应该减少由改变的免疫机制产生的疾病的活性。实验观察到各种免疫抑制剂可减少或阻止动物的初级3、4和次级5免疫应答，降低γ-球蛋白水平，6抑制速发型和迟发型超敏反应，7并诱导同种移植物功能存活状态延长。8，9此外，各种临床试验10-13表明，免疫抑制剂在系统性红斑狼疮、自身免疫性溶血性贫血、高球蛋白血症紫癜、结节性红斑和结节性多动脉炎等疾病中具有潜在的有益作用，这些疾病是通过免疫机制确定的。这些药物之一，硫唑嘌呤（Imuran）14，15已显示出足够的前景，证明在溃疡性结肠炎的临床试验。硫唑嘌呤是6-巯基嘌呤的杂环衍生物
Several informative studies have described the use of immunosuppressive agents in diseases classified as auto-immune in pathogenesis. Dameshek and Schwartz 1,2 have shown that certain antimetabolities are capable of creating a drug-induced immunologic tolerance that theoretically should reduce the activity of diseases produced by altered immune mechanisms. Various immunosuppressive agents have been observed experimentally to reduce or prevent the primary 3,4 and secondary 5 immune response in animals, decrease the level of γ-globulin, 6 inhibit immediate and delayed hypersensitivity, 7 and to induce a prolonged functionalsurvival state in homograft material. 8,9 Furthermore, various clinical trials 10-13 suggest potential beneficial effects of immunosuppressive agents in diseases such as systemic lupus erythematosus, auto-immune hemolytic anemia, hyperglobulinemia purpura, erythema nodosum, and polyarteritis nodosa, identified with immunologic mechanisms. One of these agents, azathioprine (Imuran) 14,15 has shown sufficient promise to justify a clinical trial in ulcerative colitis. Azathioprine is a heterocyclic derivative of 6-mercaptopurine